7/10/2019 Can-Fite Biopharma Downside Risk: Paid Promos, Rehashed News, And $50M Shelf - Can-Fite BioPharma Ltd. (NYSEMKT:CANF) | Seeking Alpha


https://seekingalpha.com/article/4142115-can-fite-biopharma-downside-risk-paid-promos-rehashed-news-50m-shelf 1/9


Short Ideas  |  Healthcare   |  Israel


Can­Fite Biopharma Downside Risk: Paid Promos, Rehashed News,
And $50M Shelf
Feb. 1, 2018 9:36 AM ET32 comments
by: The Street Sweeper


Summary


Can­Fite has not advanced its experimental pill for psoriasis and arthritis, despite
almost a quarter­century of effort.


The stock rally coincides with massive, orchestrated promotional campaigns, paid
for by third parties.


The stock rally also coincides with Can­Fite’s regurgitated news.


The recent $50 million stock shelf allows immediate stock sales, complete with
looming potential dilution.


Over the years, the Israel company's accumulated losses have risen to $103 million
and the stock price has dropped. Yet executive compensation has risen to $3.3
million.


Does Can­Fite Biopharma (CANF) really want investors to take it seriously? Then stop the
paid ad madness.


The Israel­based company has been focused for the past two decades on trying to
advance its experimental treatment for psoriasis and arthritis.


But the biotech acts like the real focus is selling stock … fueled by promotions that third
parties pay for in cold, hard cash.


The company has not responded to our requests for comment, but the website is here.
Meanwhile, consider the paid professional promotions, self­promotions and four other
issues that may make Can­Fite a risky investment:



https://seekingalpha.com/stock-ideas/short-ideas

https://seekingalpha.com/stock-ideas/healthcare

https://seekingalpha.com/market-outlook/global-investing/analysis/Israel

https://finance.yahoo.com/quote/canf?ltr=1

http://www.canfite.co.il/
7/10/2019 Can-Fite Biopharma Downside Risk: Paid Promos, Rehashed News, And $50M Shelf - Can-Fite BioPharma Ltd. (NYSEMKT:CANF) | Seeking Alpha


https://seekingalpha.com/article/4142115-can-fite-biopharma-downside-risk-paid-promos-rehashed-news-50m-shelf 2/9


*1. Promotions: Self­Interested Party Funds $20K Pumps


The following Can­Fite promotion – a paid ad, in reality ­­ landed in countless email boxes
last Friday, Jan. 26, 2018 …


The disclosure states: "SCS LLC has been compensated twenty thousand dollars cash via
bank wire by sunrise media for this weeks coverage of CANF."


The same basic paid advertisement arrived earlier on Jan. 26, 2018 … under a different
name:



https://static.seekingalpha.com/uploads/2018/1/30/49176349-15173278903404183_origin.png

https://static.seekingalpha.com/uploads/2018/1/30/49176349-1517327891318075_origin.png
7/10/2019 Can-Fite Biopharma Downside Risk: Paid Promos, Rehashed News, And $50M Shelf - Can-Fite BioPharma Ltd. (NYSEMKT:CANF) | Seeking Alpha


https://seekingalpha.com/article/4142115-can-fite-biopharma-downside-risk-paid-promos-rehashed-news-50m-shelf 3/9


Many people were treated to the following Can­Fite “alert” – actually, another paid ad – on
Jan. 25, 2018 …


Like the other promo pieces, the disclosure reveals …


"Our reports/releases are a commercial advertisement and are for general information
purposes ONLY. We are engaged in the business of marketing and advertising companies
for monetary compensation. Never invest in any stock featured on our site or emails



https://static.seekingalpha.com/uploads/2018/1/30/49176349-15173278920522263_origin.png

https://static.seekingalpha.com/uploads/2018/1/30/49176349-15173278912788599_origin.png
7/10/2019 Can-Fite Biopharma Downside Risk: Paid Promos, Rehashed News, And $50M Shelf - Can-Fite BioPharma Ltd. (NYSEMKT:CANF) | Seeking Alpha


https://seekingalpha.com/article/4142115-can-fite-biopharma-downside-risk-paid-promos-rehashed-news-50m-shelf 4/9


unless you can afford to lose your entire investment.


"SCS LLC has been compensated twenty thousand dollars cash via bank wire by sunrise
media for this weeks coverage of CANF."


On Jan. 25, promoters sent out another email blast:


So this promotion sent under the official­sounding name of OTCBB Journal is actually
another SCS piece.


Earlier in January, on Jan. 9, 2018, 6:20 a.m., countless email boxes were treated to
Small Cap Leader’s “Brand New NYSE Biotech Alert (Inside)”



https://static.seekingalpha.com/uploads/2018/1/30/49176349-15173278930169594_origin.png

https://static.seekingalpha.com/uploads/2018/1/30/49176349-1517327890957679_origin.png
7/10/2019 Can-Fite Biopharma Downside Risk: Paid Promos, Rehashed News, And $50M Shelf - Can-Fite BioPharma Ltd. (NYSEMKT:CANF) | Seeking Alpha


https://seekingalpha.com/article/4142115-can-fite-biopharma-downside-risk-paid-promos-rehashed-news-50m-shelf 5/9


The disclosure carries the following warning in fine print:


***


These are just a few snippets from promos sent out in the last couple of weeks.


*Here’s the deal:


> Last week alone, a third party paid at least $20,000 cash to promote Can­Fite.


>In January thus far, promoters sent at least 12 promotional alerts to countless email
boxes.


>Our research indicates third parties paid upwards of $38,000, just in the month of
January, for Can­Fite promos.


*2. How These Paid Promotions Hurt The Little Guy


We may not know the identity of the individual or group paying the third parties (Sunrise
Media and TSX Ventures), which then fund the Can­Fite promotions.


But it makes sense that the paying party is someone who owns cheaper Can­Fite shares
or has something else to gain by what will likely be a brief stock price increase.


Historically, paid promotions of Can­Fite began in late December 2013 and have
continued on­and­off throughout the years.


When the promotions hit, the stock typically rises. When the promotions vanish, people
start selling; the stock gets hammered.



http://stockpromoters.com/View-Stock-Promotions-By-Symbol.aspx

https://static.seekingalpha.com/uploads/2018/1/30/49176349-15173278912940373_origin.png

https://static.seekingalpha.com/uploads/2018/1/30/49176349-15173278911100338_origin.png
7/10/2019 Can-Fite Biopharma Downside Risk: Paid Promos, Rehashed News, And $50M Shelf - Can-Fite BioPharma Ltd. (NYSEMKT:CANF) | Seeking Alpha


https://seekingalpha.com/article/4142115-can-fite-biopharma-downside-risk-paid-promos-rehashed-news-50m-shelf 6/9


*3. Regurgitated News


Can­Fite itself seems overly promotional as it sends out upbeat news, then follows 2 1/2
weeks later with the same news, rehashed.


Last Thursday, January 25, the company announced it received about $2.2 million upfront
from Gebro Holdings under an agreement to eventually distribute the pill in Spain, Austria
and Switzerland, if the experimental drug can jump through those countries’ regulatory
hoops.


(January 25, 2018 07:00 AM Eastern Standard Time


PETACH TIKVA, Israel­­(BUSINESS WIRE)­­Can­Fite BioPharma Ltd. (NYSE American:
CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small
molecule drugs that address cancer, liver and inflammatory diseases, today announced it
has received its first payment of approximately $2,200,000 from Gebro Holdings GmbH.
Can­Fite recently announced entering into a distribution agreement with Gebro for the
exclusive right to distribute Can­Fite’s lead drug candidate, Piclidenoson (CF101), for the
treatment of rheumatoid arthritis and psoriasis in 3 European countries including Spain,
Switzerland and Austria, upon receipt of regulatory approvals.)


But, 17 days earlier, on January 8, guess what Can­Fite announced?


The company announced it had signed a distribution agreement with Gebro, which “is
making a total upfront and milestone payment of approximately $2,000,000.”


(PETACH TIKVA, Israel, January 8, 2018 ­­ Can­Fite BioPharma Ltd. (NYSE American:
CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small
molecule drugs that address cancer, liver and inflammatory diseases, today announced it
has signed a distribution agreement with Gebro Holding GmBH to distribute Can­Fite’s
lead drug candidate, Piclidenoson (CF101), for the treatment of rheumatoid arthritis and
psoriasis in 3 European countries including Spain, Switzerland and Austria, upon receipt
of regulatory approvals.


(Under the terms of the distribution agreement, Gebro is making a total upfront and
milestone payment of approximately $2,000,000 to Can­Fite. In addition, the agreement
provides that additional payments of up to approximately $7,000,000 will be received by
Can­Fite upon the achievement of certain regulatory, launch and sales milestones plus
double­digit percentage royalty payments on net sales.)



https://www.businesswire.com/

http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.canfite.com%2F&esheet=51748608&newsitemid=20180125005408&lan=en-US&anchor=Can-Fite+BioPharma+Ltd&index=1&md5=70b1c85bbf9417bb385432cda1f417d3

https://seekingalpha.com/symbol/CFBI

https://www.sec.gov/Archives/edgar/data/1536196/000121390018000220/f6k010818ex99-1_canfitebio.htm

https://seekingalpha.com/symbol/CFBI
7/10/2019 Can-Fite Biopharma Downside Risk: Paid Promos, Rehashed News, And $50M Shelf - Can-Fite BioPharma Ltd. (NYSEMKT:CANF) | Seeking Alpha


https://seekingalpha.com/article/4142115-can-fite-biopharma-downside-risk-paid-promos-rehashed-news-50m-shelf 7/9


The stock rocketed about 15% on the first news (Jan. 8) and over 35% after the second
release (Jan. 25).


In both cases, the company’s releases also coincide with the paid professional
promotions of Jan. 8 – Jan. 9 and Jan. 25 – Jan. 26… which coincide with the
ongoing stock rally.


(Source: Marketwatch)


*4. Drug Prospect Cast Off: Partner Bows Out


Meanwhile, the company’s drug candidate hasn’t exactly grabbed the world by the tail.


In 2006, Seikagaku inked a deal to distribute Can­Fite’s drug candidate in Japan. The
company got $3 million upfront and … much like the company is doing with the Gebro
deal … trumpeted the deal as tremendously valuable.


But after nine years, Seikagaku terminated the agreement.


Overnight, that much­touted $17 million deal vanished.


But the long­time distributor would not have cast off the drug … if it had been valuable.


*5. Stock Price Drops … Executive Compensation Rises


While Can­Fite’s stock price dropped and accumulated losses grew to $103 million over
the years, the two top executives’ compensation rose to $3.3 million.



https://www.sec.gov/Archives/edgar/data/1536196/000114420414019279/v373060_20f.htm

https://static.seekingalpha.com/uploads/2018/1/30/49176349-15173278911601698_origin.png
7/10/2019 Can-Fite Biopharma Downside Risk: Paid Promos, Rehashed News, And $50M Shelf - Can-Fite BioPharma Ltd. (NYSEMKT:CANF) | Seeking Alpha


https://seekingalpha.com/article/4142115-can-fite-biopharma-downside-risk-paid-promos-rehashed-news-50m-shelf 8/9


(Source: Morningstar)


*6. The Shelf


The entire thing ­we’ve notified the SEC that the stock may be showing characteristics of
an unfolding pump­and­dump – has been tied up by one little, frayed bow… a shelf
registration.


Can­Fite filed the shelf in October to sell up to $50 million in stock. The stock can be sold
anytime and may be accompanied by potential dilution.


(Source: Company SEC filing)


*Conclusion



https://static.seekingalpha.com/uploads/2018/1/30/49176349-15173278910882125_origin.png

https://static.seekingalpha.com/uploads/2018/1/30/49176349-15173278910788043_origin.png

https://static.seekingalpha.com/uploads/2018/1/30/49176349-1517328155111768_origin.png
7/10/2019 Can-Fite Biopharma Downside Risk: Paid Promos, Rehashed News, And $50M Shelf - Can-Fite BioPharma Ltd. (NYSEMKT:CANF) | Seeking Alpha


https://seekingalpha.com/article/4142115-can-fite-biopharma-downside-risk-paid-promos-rehashed-news-50m-shelf 9/9


Professional and company promotions, naïve investors and momentum traders have likely
fueled the Can­Fite buying frenzy to drive what we believe is an overvalued stock.


The company has existed for 24 years and hasn’t even gotten its product beyond Phase
III recruiting in Israel; recruiting is an initial step into the typical 6­to­11­year process of
human testing. Can­Fite is riding on a carpet of paid promotions that have plumped the
stock up to around $2.50, creating a hefty $80­plus million market valuation.


This Can­Fite, Can’t­Win stock in our opinion will unravel soon by 30% … and later drop
into penny stock land.


Disclosure: I am/we are short CANF. I wrote this article myself, and it expresses my own opinions. I am not receiving
compensation for it. I have no business relationship with any company whose stock is mentioned in this article.


JOIN THE CONVERSATION


